Axitinib—a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor

Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257

Rini BI, Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23:1028–1043

Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027

Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676

Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306–1309

Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L (2003) VEGF-receptor signal transduction. Trends Biochem Sci 28:488–494

Nilsson M, Heymach JV (2006) Vascular endothelial growth factor (VEGF) pathway. J Thorac Oncol 1:768–770

Terman BI, Carrion ME, Kovacs E, Rasmussen BA, Eddy RL, Shows TB (1991) Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6:1677–1683

Sait SN, Dougher-Vermazen M, Shows TB, Terman BI (1995) The kinase insert domain receptor gene (KDR) has been relocated to chromosome 4q11–>q12. Cytogenet Cell Genet 70:145–146

Shibuya M (2002) Vascular endothelial growth factor receptor family genes: when did the three genes phylogenetically segregate? Biol Chem 383:1573–1579

Takahashi T, Shibuya M (1997) The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 14:2079–2089

Rugo HS, Herbst RS, Liu G et al (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23:5474–5483

Hu-Lowe DD, Zou HY, Grazzini ML et al (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14:7272–7283

Wilmes LJ, Pallavicini MG, Fleming LM et al (2007) AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 25:319–327

Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434

Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134

Motzer RJ, Michaelson MD, Redman BG et al (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16–24

Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124

Rixe O, Bukowski RM, Michaelson MD et al (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8:975–984

Rixe O, Meric J-B, Bloch J et al (2005) Surrogate markers of activity of AG-013736, a multi-target tyrosine kinase receptor inhibitor, in metastatic renal cell cancer (RCC). J Clin Oncol 23:3003 (Meeting Abstracts)

Rini BI, Wilding GT, Hudes G et al (2007) Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol 25:5032 (Meeting Abstracts)

Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413

Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966

Philip PA, Benedetti J, Fenoglio-Preiser C et al (2007) Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol 25:LBA4509 (Meeting Abstracts)

Korc M (2003) Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2:8

Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K (2000) High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88:2239–2245

Niedergethmann M, Hildenbrand R, Wostbrock B et al (2002) High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 25:122–129

Kindler HL, Niedzwiecki D, Hollis D et al (2007) A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB. J Clin Oncol 25:4508 (Meeting Abstracts)

Spano JP, Chodkiewicz C, Maurel J et al (2008) Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 371:2101–2108

Phase II study of AG-013736 in combination with docetaxel versus docetaxel alone for patients with metastatic breast cancer. Clinicaltrials.gov 2006 July 25. http://clinicaltrials.gov/ct2/show/NCT00076024 . Accessed on 15 Oct 2009

Rugo HS, Stopeck A, Joy AA et al (2007) A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC). J Clin Oncol 25:1003 (Meeting Abstracts)

Cupisti K, Wolf A, Raffel A et al (2007) Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution’s experience over 20 years. Ann Surg 246:815–821

Gottlieb JA, Hill CS Jr (1974) Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med 290:193–197

Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155–2160

Viglietto G, Maglione D, Rambaldi M et al (1995) Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11:1569–1579

Kilicarslan AB, Ogus M, Arici C, Pestereli HE, Cakir M, Karpuzoglu G (2003) Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas. APMIS 111:439–443

Klein M, Picard E, Vignaud JM et al (1999) Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 161:41–49

Cohen EE, Rosen LS, Vokes EE et al (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708–4713

Schiller JH, Larson T, Ou SI et al (2007) Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II trial. J Clin Oncol 25:7507 (Meeting Abstracts)

Fruehauf JP, Lutzky J, McDermott DF et al (2008) Axitinib (AG-013736) in patients with metastatic melanoma: a phase II study. J Clin Oncol 26:9006 (Meeting Abstracts)

Phase II study with AG-013736 combined with chemotherapy and bevacizumab in patients with metastatic colorectal cancer. Clinicaltrials.gov 2008 April 17. http://clinicaltrials.gov/ct2/show/NCT00460603 . Accessed 15 Oct 2009

A study combining FOLFOX or FOLFIRI with AG-013736 or avastin in patients with metastatic colorectal cancer after failure of one first line regimen. Clinicatrials.gov 2008 April 07. http://clinicaltrials.gov/ct2/show/NCT00615056 . Accessed 15 Oct 2009

Randomized study of gemcitabine plus AG-013736 versus gemcitabine for advanced pancreatic cancer. Clinicaltrials.gov 2007 May 07. http://clinicaltrials.gov/ct2/show/NCT00471146 . Accessed 15 Oct 2009

Axitinib as second line therapy for metastatic renal cell cancer: Axis trial. Clinicaltrials.gov 2009. http://clinicaltrials.gov/ct2/show/NCT00678392 . Accessed 15 Oct 2009

Karaman MW, Herrgard S, Treiber DK et al (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127–132

Rixe O, Dutcher JP, Motzer RJ (2008) Association between diastolic blood pressure ≥90 mmHg and efficacy in patients with metastatic renal cell carcinoma receiving axitinib (AG-013736). ESMO 2008 Meeting abstract

Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA (2008) Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. J Clin Oncol 26:4047–4048

Tam BY, Wei K, Rudge JS et al (2006) VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 12:793–800

Boutin AT, Weidemann A, Fu Z et al (2008) Epidermal sensing of oxygen is essential for systemic hypoxic response. Cell 133:223–234